We are fairly close in our positions on these two. I am not arguing against FGEN risk/reward at current price - I would if stock were double of current price at this time point - just pointed out the differences and perceptions. FGEN is a marathon compared to ENTA ph3 clinical programs, which is why it is harder to quantify risk, for me anyway.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.